New York State Common Retirement Fund increased its position in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) by 40.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 11,508 shares of the company’s stock after buying an additional 3,308 shares during the quarter. New York State Common Retirement Fund’s holdings in Bolt Biotherapeutics were worth $178,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors and hedge funds have also recently modified their holdings of BOLT. The Manufacturers Life Insurance Company purchased a new position in shares of Bolt Biotherapeutics in the 1st quarter worth $240,000. Victory Capital Management Inc. purchased a new position in shares of Bolt Biotherapeutics in the 1st quarter worth $390,000. Rhumbline Advisers purchased a new position in shares of Bolt Biotherapeutics in the 1st quarter worth $355,000. American International Group Inc. purchased a new position in shares of Bolt Biotherapeutics in the 1st quarter worth $243,000. Finally, BlackRock Inc. purchased a new position in shares of Bolt Biotherapeutics in the 1st quarter worth $27,617,000. 86.36% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ BOLT opened at $13.96 on Tuesday. The company has a quick ratio of 12.89, a current ratio of 12.89 and a debt-to-equity ratio of 0.08. The firm’s 50-day moving average price is $14.30 and its two-hundred day moving average price is $19.73. Bolt Biotherapeutics, Inc. has a 52-week low of $10.75 and a 52-week high of $43.07. The stock has a market capitalization of $519.33 million and a P/E ratio of -0.63.
Several brokerages recently issued reports on BOLT. Zacks Investment Research downgraded Bolt Biotherapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, August 17th. SVB Leerink lifted their price target on Bolt Biotherapeutics from $34.00 to $35.00 and gave the stock an “outperform” rating in a research note on Monday, August 16th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $40.50.
Bolt Biotherapeutics Company Profile
Bolt Biotherapeutics, Inc, a clinical-stage immuno-oncology company, engages in the discovery, development, and commercialization of pharmaceutical products. The company develops BDC-1001, a human epidermal growth factor receptor 2 (HER2) for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; and BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers.
Read More: How to interpret the current ratio
Want to see what other hedge funds are holding BOLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bolt Biotherapeutics, Inc. (NASDAQ:BOLT).
Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.